Findings

What do systematic reviews say?

5 questions · 5 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 1 · 20%Low 2 · 40%Moderate 1 · 20%High 0 · 0%

Anticoagulant vs no treatment

Major bleeding · people hospitalised with COVID‐19

It is very uncertain whether anticoagulants changes major bleeding compared with no treatment (very low certainty).

1 finding from 1 review

Anticoagulants for people hospitalised with COVID‐19: a rapid review 2022 · Cochrane Headline outcomes only
RR 1.19 [0.66, 2.12]
2 studies · 7218 participants
Very low

Higher‐dose anticoagulants vs lower‐dose anticoagulants

Major bleeding · people hospitalised with COVID‐19

Higher‐dose anticoagulants probably leads to higher major bleeding compared with lower‐dose anticoagulants (moderate certainty).

1 finding from 1 review

Anticoagulants for people hospitalised with COVID‐19: a rapid review 2022 · Cochrane Headline outcomes only
RR 1.78 [1.13, 2.8]
4 studies · 4400 participants
Moderate

DOAC vs variable dose warfarin

Major bleeding · atrial fibrillation patients with CKD

Direct oral anticoagulants (DOAC) showed no clear difference in major bleeding compared with warfarin (low certainty).

1 finding from 1 review

Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation… 2017 · Cochrane Headline outcomes only
RR 0.79 [0.59, 1.04]
5 studies · 12521 participants
Low

Anticoagulants (chosen at investigators' discretion) vs placebo

Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Anticoagulants (chosen at investigators' discretion) showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).

1 finding from 1 review

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or… 2016 · Cochrane Headline outcomes only
OR 5.05 [0.24, 105.76]
1 study · 557 participants
Low

Anticoagulants (chosen at investigators' discretion) vs placebo

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found